3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
14
Colorectal Neoplasms
13
Rectal Neoplasms
5
Colonic Neoplasms
4
Adenocarcinoma
4
Liver Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Neoplasm Metastasis
2
Melanoma
2
Esophageal Neoplasms
2
Barrett Esophagus
2
Adenocarcinoma Of Esophagus
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Resectable Pancreatic Ductal Adenocarcinoma
1
Prostatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Ovarian Neoplasms
1
Obesity
1
Non-DM Stage II High-risk Colorectal Cancer
1
Neoplasms
1
Motor Activity
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Insulin Resistance
1
Hepatitis C, Chronic
1
Glioma
1
Interventions
Ribavirin
4
ledipasvir
2
Sofosbuvir
2
sofosbuvir-velpatasvir drug combination
1
peginterferon alfa-2a
1
ledipasvir, sofosbuvir drug combination
1
daclatasvir
1
Viusid
1
Simeprevir
1
Metformin
1
Introns
1
Dietary Supplements
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hepatitis C, Chronic
×
Metformin
×
Gastrointestinal
×
Clear all
NCT02319200
2017-01-11
METFOVIR
Assistance Publique - Hôpitaux de Paris
Phase 3
Terminated
11 enrolled